Get the Daily Brief
Latest Biotech News
Targeted oncology—drug resistance, immune evasion and biomarker biology
New cancer biology work mapped why immunotherapy can fail and how tumors rewire cell death and metabolism. A study described chromosomal chaos in tumors as a potential driver of immune blindness,...
Gene editing and precision delivery—improving specificity and getting payload into the right cells
Aptamer-guided CRISPR-Cas9 delivery drew focus as a precision-editing approach aimed at overcoming one of the field’s biggest bottlenecks: getting the editing machinery into tumor cells while...
Clinical diagnostics and precision imaging—faster reads, better target confirmation
Digital pathology and imaging automation moved closer to routine workflows. A new browser-based TMA-grid tool was introduced to bring FAIR, zero-footprint de-arraying to digital pathology,...
Oncology clinical trials—signals for new therapies and caution on negative or neutral reads
Several trial-focused updates highlighted where oncology development is moving fastest and where strategy is meeting friction. A randomized Phase 2 DeLLphi-309 report on tarlatamab extended dosing...
Immunology and cellular engineering—boosting T cells and reshaping immune landscapes
Engineering immune cells remained a high-velocity area. A report described engineered T cell receptors with built-in ICOS signaling that aimed to deliver long-lasting anti-tumor activity,...
Antimicrobial resistance and infectious disease surveillance—measuring shifting resistance patterns
Resistance in bacterial pathogens kept pressure on surveillance and diagnostics. A study on Neisseria gonorrhoeae highlighted azithromycin resistance shifts at the genetic level, raising...
Cardiometabolic and kidney—clinical measurements and evidence for monitoring during therapy
Cardiometabolic risk management moved forward with practical signals for monitoring and understanding disease biology. A real-world study reported that Nefecon, a targeted-release budesonide...
Regenerative and drug development platforms—aging clocks and human-translatable endpoints
Aging interventions moved closer to clinical translation with an aging endpoint shift. A Proteomic Aging Clock entered the clinic in a landmark Phase 2a geroprotection trial, positioning...
Biotech investing and corporate pipeline timing—market read-throughs on clinical event milestones
SELLAS Life Sciences stock volatility reflected investor focus on unresolved binary clinical milestones rather than confirmed negative results. In a report on the company’s sharp decline, the...
Small cell lung cancer immunotherapy advances
Subcutaneous tarlatamab generated early safety and activity signals in extensive-stage small cell lung cancer, with the phase 1b DeLLphi-308 study suggesting a potentially easier administration...
Checkpoint inhibitor biology under scrutiny
A translational modeling study in the British Journal of Cancer challenged a core assumption behind pembrolizumab dosing—that receptor occupancy alone predicts immune activation. The work reported...
Cancer immunotherapy strategy revisited
A research storyline aimed at solid tumors is again testing a long-held immunotherapy premise: whether T cells must be antigen-specific to eliminate cancer. In discussion of an intratumoral T-cell...
New clinical signal for an IgA nephropathy therapy in the real world
A real-world dataset reported that Nefecon—targeted-release budesonide—reduced proteinuria and helped preserve kidney function in primary IgA nephropathy, including patients starting at relatively...
Lung cancer trial setback for antibody-drug plus PD-1 strategy
A first-line phase 3 trial reported that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free survival in metastatic PD-L1-high lung cancer. The result marks a...
SMA muscle-loss drug wins FDA approval
The FDA approved Scholar Rock’s Isembyld (sponsored as a therapy targeting muscle loss in spinal muscular atrophy) for adults and children aged 2 and older who are already receiving SMN2-targeting...
Oncology trial design and outcome interpretation debate
A commentary in the Journal of Cancer Research and Clinical Oncology challenged how clinicians interpret exceptional individual responses in multiple myeloma case narratives involving melflufen....
Cancer genomics and treatment resistance mechanisms
A new study linked a hidden RNA modification to ferroptosis escape and chemotherapy resistance in pancreatic cancer, identifying a mechanism that helps tumors withstand gemcitabine exposure. The...
Surgical and clinical workflow optimization in oncology care
A multicenter phase II study in Japan reported that preoperative chemotherapy using docetaxel, cisplatin, and 5-fluorouracil enabled most patients with HPV-linked oropharyngeal cancer to avoid...
AI-enabled diagnostics and clinical decision support
A study reported an AI model that can read pathology slides and answer clinician questions across 31 cancer types, aiming to streamline interpretation workflows that traditionally depend on...
FDA approval – SMA muscle loss therapy
The FDA approved Scholar Rock’s Isembyld (ise-mbyld) as the first therapy targeting muscle loss in spinal muscular atrophy (SMA). The approval covers adults and children age 2 years and older who...